Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Basilea Pharmaceutica International AG Allschwil has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed across 3 distinct examiners and 3 distinct art units. SEAMAN, D MARGARET M is the busiest examiner, with 1 pending office action. The data shows a 1 to 1 ratio between pending actions and examiners.
With 3 pending office actions and 3 distinct examiners, the company's prosecution is not concentrated under any single official. The involvement of 3 distinct art units further indicates that each matter is being reviewed by a different specialized group within the Biotechnology & Pharmaceuticals sector. SEAMAN, D MARGARET M is the busiest examiner, but her 1 pending office action is equal to the workload of every other examiner in the portfolio. This distribution across 3 distinct examiners and 3 distinct art units suggests that the company's current filings are diverse enough to require review from multiple USPTO units. Practitioners can observe that the 3 pending actions are being handled independently by 3 different officials, ensuring a variety of perspectives across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18483703 | METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS | SHOWALTER, ALEXANDER KEITH | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18483703 | METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS | SHOWALTER, ALEXANDER KEITH | 34d |
| 18002012 | COMPOUNDS AND METHODS FOR TREATING FUNGAL INFECTIONS | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1629 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905680 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | SEAMAN, D MARGARET M | 1625 | §102DP | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18483703 | METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS | SHOWALTER, ALEXANDER KEITH | 1629 | §102§103§112 | Final Rejection | 34d | Pending | Oct 10, 2023 |
| 18002012 | COMPOUNDS AND METHODS FOR TREATING FUNGAL INFECTIONS | HERNANDEZ, JACKSON J | 1627 | DP | Final Rejection | — | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBasilea Pharmaceutica International AG Allschwil has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
D Margaret M Seaman has the most, with 1 of Basilea Pharmaceutica International AG Allschwil's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
